Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study
Computed predictions of PFS and OS confirmed treatment efficiency and good patient survival. RLT should be considered a safe and reliable line of treatment for patients with progressive NENs as it causes only a low number of low-grade adverse events.
Authors
- Katarzyna Jóźwik−Plebanek (ORCID: https://orcid.org/0000-0002-6756-5415)
- Beata Kos‐Kudła (ORCID: https://orcid.org/0000-0003-3755-1722)
- Dorota Brodowska-Kania (ORCID: https://orcid.org/0000-0002-3328-1537)
- Marek Saracyn (ORCID: https://orcid.org/0000-0002-5800-0500)
- Beata Dmochowska (ORCID: https://orcid.org/0009-0009-2658-8512)
- Adam Daniel Durma (ORCID: https://orcid.org/0000-0001-7103-2577)
- Maciej Kołodziej (ORCID: https://orcid.org/0000-0003-1943-264X)
- Grzegorz Kamiński (ORCID: https://orcid.org/0000-0002-2357-0634)
- Adrianna Mróz (ORCID: https://orcid.org/0009-0009-7127-6892)
Institutions
- Medical University of Silesia (PL)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3390/cancers16203509
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.39